FDA Approves New Parkinson's Disease Medication JUVMO

The U.S. FDA has approved AbbVie's JUVMO (tavapadon) tablets for adults with Parkinson's disease. This first-in-class selective D1/D5 receptor agonist represents a significant advance in motor symptom control, being the first new dopaminergic treatment in decades. Its approval is based on Phase 3 trial data demonstrating efficacy and a favorable safety profile.